High-level Azithromycin Resistance Occurs in Neisseria Gonorrhoeae As a Result of a Single Point Mutation in the 23S RRNA Genes
Overview
Affiliations
High-level azithromycin resistance (AZM-HR), defined as a MIC of > or = 256 mg/liter, emerged in Neisseria gonorrhoeae in the United Kingdom in 2004. To determine the mechanism of this novel phenotype, isolates from the United Kingdom that were AZM-HR (n, 19), moderately AZM resistant (MICs, 2 to 8 mg/liter) (n, 26), or sensitive (MICs, 0.12 to 0.25 mg/liter) (n, 4) were screened for methylase (erm) genes and for mutations in the mtrR promoter region, associated with efflux pump upregulation. All AZM-resistant isolates and 12 sensitive isolates were screened for mutations in domain V of each 23S rRNA allele. All AZM-HR isolates contained the A2059G mutation (Escherichia coli numbering) in three (3 isolates) or four (16 isolates) 23S rRNA alleles. Most (22/26) moderately AZM resistant isolates contained the C2611T mutation in at least 3/4 alleles. The remainder contained four wild-type alleles, as did 8/12 sensitive isolates, while one allele was mutated in the remaining four sensitive isolates. Serial passage of AZM-sensitive colonies on an erythromycin-containing medium selected AZM-HR if the parent strain already contained mutation A2059G in one 23S rRNA allele. The resultant AZM-HR strains contained four mutated alleles. Eight isolates (five moderately AZM resistant and three AZM-HR) contained mutations in the mtrR promoter. No methylase genes were detected. This is the first evidence that AZM-HR in gonococci may result from a single point mutation (A2059G) in the peptidyltransferase loop in domain V of the 23S rRNA gene. Mutation of a single allele is insufficient to confer AZM-HR, but AZM-HR can develop under selection pressure. The description of a novel resistance mechanism will aid in screening for the AZM-HR phenotype.
Roditscheff A, Egli K, Vianin A, Lortscher F, Reidla J, Wehrli F Eur J Clin Microbiol Infect Dis. 2025; .
PMID: 39930296 DOI: 10.1007/s10096-025-05053-4.
Antimicrobial Resistance in Curable Sexually Transmitted Infections.
Giacani L, Bradshaw C, Muzny C, Graves K, Pasricha S, Jordan S Curr HIV/AIDS Rep. 2025; 22(1):14.
PMID: 39856345 DOI: 10.1007/s11904-025-00722-7.
Local emergence and global evolution of with high-level resistance to azithromycin.
Melendez J, Edwards V, Muniz Tirado A, Hardick J, Mehta A, Aluvathingal J Antimicrob Agents Chemother. 2024; 68(12):e0092724.
PMID: 39445818 PMC: 11619321. DOI: 10.1128/aac.00927-24.
Mauffrey F, Poncet F, Jacot D, Greub G, Nordmann P, Blanc D PLoS One. 2024; 19(7):e0306695.
PMID: 39012901 PMC: 11251580. DOI: 10.1371/journal.pone.0306695.
Unemo M, Sanchez-Buso L, Golparian D, Jacobsson S, Shimuta K, Lan P J Antimicrob Chemother. 2024; 79(8):1885-1899.
PMID: 38889110 PMC: 11290888. DOI: 10.1093/jac/dkae176.